⌘K
Loading ticker…
ArriVent BioPharma, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, ArriVent BioPharma, Inc. Common Stock (AVBP) has a 3-month relative strength percentile of 91 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 68. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.7%, relative volume 2.84×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 91, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
AVBP is in a stage 2 uptrend, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 13.4% / 43.3%.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
AVBP is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $27M notional. Top 3 carry $61M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $27M |
| IWMiShares Russell 2000 ETF | 0.02% | $18M |
| XBIState Street SPDR S&P Biotech ETF | 0.22% | $16M |
| VXFVanguard Extended Market ETF | 0.01% | $8M |
| IWOiShares Russell 2000 Growth ETF | 0.05% | $6M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $1M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AVBP Jan avg: 8.89% median: 7.75% win: 100% σ: 2.52% n: 3 2024-01-29 → 2026-05-29 | AVBP Feb avg: -5.06% median: -0.05% win: 33% σ: 10.63% n: 3 2024-01-29 → 2026-05-29 | AVBP Mar avg: -12.78% median: -17.08% win: 33% σ: 11.67% n: 3 2024-01-29 → 2026-05-29 | AVBP Apr avg: 14.08% median: 14.98% win: 67% σ: 21.15% n: 3 2024-01-29 → 2026-05-29 | AVBP May avg: 4.94% median: -0.05% win: 33% σ: 10.95% n: 3 2024-01-29 → 2026-05-29 | AVBP Jun avg: -0.99% median: -0.99% win: 50% σ: 4.86% n: 2 2024-01-29 → 2026-05-29 (current) | AVBP Jul avg: 3.84% median: 3.84% win: 50% σ: 20.11% n: 2 2024-01-29 → 2026-05-29 | AVBP Aug avg: 10.03% median: 10.03% win: 50% σ: 17.01% n: 2 2024-01-29 → 2026-05-29 | AVBP Sep avg: -7.79% median: -7.79% win: 0% σ: 6.07% n: 2 2024-01-29 → 2026-05-29 | AVBP Oct avg: 13.18% median: 13.18% win: 100% σ: 16.50% n: 2 2024-01-29 → 2026-05-29 | AVBP Nov avg: 12.29% median: 12.29% win: 100% σ: 14.40% n: 2 2024-01-29 → 2026-05-29 | AVBP Dec avg: -11.69% median: -11.69% win: 0% σ: 0.86% n: 2 2024-01-29 → 2026-05-29 |